{
  "id": "mhgap#risk_safety_2156853d",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "University Institute of Mental Health, China; Pichayanan (Peach) Wattanavitukul, Faculty of Medicine Ramathibodi Hospital, Mahidol University and Alzheimer’s Disease and Related Disorder Association, Thailand; and Enat Yewnetu, CareEpilepsy, Ethiopia. v Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders Thanks are also due to the members of the External Review Group (ERG): Helal Uddin Ahmed, National Institute of Mental Health, Bangladesh; Kaarin Anstey, University of New South Wales, Austalia; Helen Herrman, Orygen, The National Centre of Excellence in Youth Mental Health and University of Melbourne, Australia; Lola Kola, University of Ibadan, Nigeria, and University of Washington, USA; Crick Lund, King’s College London, United Kingdom and University of Cape Town, South Africa; David Ndetei, University of Nairobi, Kenya; Alfredo Pemjean, Secretariat for Public Health, Ministry of Health, Chile; Pratap Sharan, All India Institute of Medical Sciences, India; Vandad Sharifi Senejani, Department of Psychiatry and Tehran University of Medical Sciences, Islamic Republic of Iran; David Shiers, Psychosis Research Unit, Greater Manchester Mental Health Trust, Division of Psychology and Mental Health, University of Manchester, United Kingdom; Gagandeep Singh, Department of Neurology, Dayanand Medical College, India; Sahar Vasquez, Mind Health Connect, Belize; and Min Zhao, Shanghai Drug Abuse Treatment Center and Shanghai Mental Health Center and Shanghai Jiaotong University School of Medicine, China. The WHO Steering Group for the guideline comprised staff from across WHO. From the WHO Department of Mental Health and Substance Use: Ken Carswell, Sudipto Chatterjee, Batool Fatima, Alexandra Fleischmann, Michelle Funk, Brandon Gray, Charlotte Hanlon, Fahmy Hanna, Dzmitry Krupchanka, Aiysha Malik, Mark van Ommeren, Vladimir Poznyak, Katrin Seeher, Chiara Servili, Inka Weissbecker. From the WHO regional offices: Florence Baingana (Regional Office for Africa), Luis Alfonzo Bello (Regional Office for the Americas, also know as the Pan American Health Organization [PAHO]), Andrea Bruni (Regional Office for South-East Asia), Ana Carina Jorge Dos Santos Ferreira Borges Bigot (PAHO), Chencho Dorji (Regional Office for South-East Asia), Martin Vandendyck (Regional Office for the Western Pacific), Ledia Lazeri (Regional Office for Europe), Maristela Goldnadel Monteiro (PAHO), Manju Rani (Regional Office for South-East Asia), Khalid Saeed (Regional Office for the Eastern Mediterranean), Renato Oliveira e Souza (PAHO). From other departments at WHO headquarters: Wole Ameyan (Department of Global HIV, Hepatitis, STI programme), Valentina Baltag (Department of Maternal, Newborn, Child and Adolescent Health and Ageing), Francesco Branca (Department of Nutrition and Food Safety), Bernadette Cappello (Health Product Policy and Standards Department), Giorgio Cometto (Health Workforce Department), Suraya Dalil (WHO Special Programme on Primary Health Care), Albis Gabrielli (Department of Neglected Tropical Diseases), Benedikt Huttner (Health Product Policy and Standards Department), Ernesto Jaramillo (WHO Global TB Programme), Taskeen Khan (Department of Noncommunicable Diseases), Jonathan King (Department of Neglected Tropical Diseases), Ruediger Krech (Department of Health Promotion), Nathalie Roebbel (Department of Social Determinants of Health), Nhan Tran (Department of Social Determinants of Health), Yuka Sumi (Department of Maternal, Newborn, Child and Adolescent Health and Ageing), Shams Syed (Special Programme on Primary Health Care). WHO would also like to thank the Topic Expert Group members and the members of the evidence review and synthesis teams for their contributions to the guideline. Details for all contributors to the guideline can be found in Annex 1. Financial support for the development of this guideline was provided by the Norwegian Programme for Capacity Development in Higher Education and Research for Development, the Swiss Agency for Development and Cooperation, and the Wellcome Trust. vi",
  "gloss_vi": "University institute of mental health, china; pichayanan (peach) wattanavitukul, faculty of medicine ramathibodi hospital, mahidol university and alzheimer’s disease and related disorder association, thailand; and enat y...",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "psychoeducation",
      "management"
    ],
    "life_topics": [
      "work"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn University Institute of Mental Health, China; Pichayanan (Peach) Wattanavitukul, Faculty of Medicine Ramathibodi Hospital, Mahidol University and Alzheimer’s Disease and Related Disorder Association, Thailand; and Enat Yewnetu, CareEpilepsy, Ethiopia. v Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders Thanks are also due to the members of the External Review Group (ERG): Helal Uddin Ahmed, National Institute of Mental Health, Bangladesh; Kaarin Anstey, University of New South Wales, Austalia; Helen Herrman, Orygen, The National Centre of Excellence in Youth Mental Health and University of Melbourne, Australia; Lola Kola, University of Ibadan, Nigeria, and University of Washington, USA; Crick Lund, King’s College London, United Kingdom and University of Cape Town, South Africa; David Ndetei, University of Nairobi, Kenya; Alfredo Pemjean, Secretariat for Public Health, Ministry of Health, Chile; Pratap Sharan, All India Institute of Medical Sciences, India; Vandad Sharifi Senejani, Department of Psychiatry and Tehran University of Medical Sciences, Islamic Republic of Iran; David Shiers, Psychosis Research Unit, Greater Manchester Mental Health Trust, Division of Psychology and Mental Health, University of Manchester, United Kingdom; Gagandeep Singh, Department of Neurology, Dayanand Medical College, India; Sahar Vasquez, Mind Health Connect, Belize; and Min Zhao, Shanghai Drug Abuse Treatment Center and Shanghai Mental Health Center and Shanghai Jiaotong University School of Medicine, China. The WHO Steering Group for the guideline comprised staff from across WHO. From the WHO Department of Mental Health and Substance Use: Ken Carswell, Sudipto Chatterjee, Batool Fatima, Alexandra Fleischmann, Michelle Funk, Brandon Gray, Charlotte Hanlon, Fahmy Hanna, Dzmitry Krupchanka, Aiysha Malik, Mark van Ommeren, Vladimir Poznyak, Katrin Seeher, Chiara Servili, Inka Weissbecker. From the WHO regional offices: Florence Baingana (Regional Office for Africa), Luis Alfonzo Bello (Regional Office for the Americas, also know as the Pan American Health Organization [PAHO]), Andrea Bruni (Regional Office for South-East Asia), Ana Carina Jorge Dos Santos Ferreira Borges Bigot (PAHO), Chencho Dorji (Regional Office for South-East Asia), Martin Vandendyck (Regional Office for the Western Pacific), Ledia Lazeri (Regional Office for Europe), Maristela Goldnadel Monteiro (PAHO), Manju Rani (Regional Office for South-East Asia), Khalid Saeed (Regional Office for the Eastern Mediterranean), Renato Oliveira e Souza (PAHO). From other departments at WHO headquarters: Wole Ameyan (Department of Global HIV, Hepatitis, STI programme), Valentina Baltag (Department of Maternal, Newborn, Child and Adolescent Health and Ageing), Francesco Branca (Department of Nutrition and Food Safety), Bernadette Cappello (Health Product Policy and Standards Department), Giorgio Cometto (Health Workforce Department), Suraya Dalil (WHO Special Programme on Primary Health Care), Albis Gabrielli (Department of Neglected Tropical Diseases), Benedikt Huttner (Health Product Policy and Standards Department), Ernesto Jaramillo (WHO Global TB Programme), Taskeen Khan (Department of Noncommunicable Diseases), Jonathan King (Department of Neglected Tropical Diseases), Ruediger Krech (Department of Health Promotion), Nathalie Roebbel (Department of Social Determinants of Health), Nhan Tran (Department of Social Determinants of Health), Yuka Sumi (Department of Maternal, Newborn, Child and Adolescent Health and Ageing), Shams Syed (Special Programme on Primary Health Care). WHO would also like to thank the Topic Expert Group members and the members of the evidence review and synthesis teams for their contributions to the guideline. Details for all contributors to the guideline can be found in Annex 1. Financial support for the development of this guideline was provided by the Norwegian Programme for Capacity Development in Higher Education and Research for Development, the Swiss Agency for Development and Cooperation, and the Wellcome Trust. vi University institute of mental health, china; pichayanan (peach) wattanavitukul, faculty of medicine ramathibodi hospital, mahidol university and alzheimer’s disease and related disorder association, thailand; and enat y..."
}